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Abstract
Background
Beta-2 Microglobulin (β2M) is a prototypical “middle molecule” uremic toxin that has been
associated with a higher risk of death in hemodialysis patients. A quantitative description of
the relative importance of factors determining β2M concentrations among patients with
impaired kidney function is currently lacking.
Methods
Herein we undertook a systematic review of existing studies reporting patient level data con-
cerning generation, elimination and distribution of β2M in order to develop a population
model of β2M kinetics. We used this model and previously determined relationships
between predialysis β2M concentration and survival, to simulate the population distribution
of predialysis β2M and the associated relative risk (RR) of death in patients receiving con-
ventional thrice-weekly hemodialysis with low flux (LF) and high flux (HF) dialyzers, short
(SD) and long daily (LD) HF hemodialysis sessions and on-line hemodiafiltration at different
levels of residual renal function (RRF).
Results
We identified 9 studies of 106 individuals and 156 evaluations of or more compartmental
kinetic parameters of β2M. These studies used a variety of experimental methods to deter-
mine β2M kinetics ranging from isotopic dilution to profiling of intra/inter dialytic concentra-
tion changes. Most of the patients (74/106) were on dialysis with minimal RRF, thus
facilitating the estimation of non-renal elimination kinetics of β2M. In large scale (N = 10000)
simulations of individuals drawn from the population of β2M kinetic parameters, we found
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that, higher dialytic removal materially affects β2M exposures only when RRF (renal clear-
ance of β2M) was below 2 ml/min. In patients initiating conventional HF hemodialysis, total
loss of RRF was predicted to be associated with a RR of death of more than 20%. Hemodia-
filtration and daily dialysis may decrease the high risk of death of anuric patients by 10% rel-
ative to conventional, thrice weekly HF dialysis. Only daily long sessions of hemodialysis
consistently reduced mortality risk between 7–19% across the range of β2M generation
rate.
Conclusions
Preservation of RRF should be considered one of the therapeutic goals of hemodialysis
practice. Randomized controlled trials of novel dialysis modalities may require large sample
sizes to detect an effect on clinical outcomes even if they enroll anuric patients. The devel-
oped population model for β2M may allow personalization of hemodialysis prescription and/
or facilitate the design of such studies by identifying patients with higher β2M generation
rate.
Introduction
Beta 2 Microglobulin (β2M) is an 11.6 kDa protein expressed in the surface of every nucleated
cell, where it non-covalently associates with the alpha-chain of the Major Histocompatibility
Complex I (MHC-I)/Human Leukocyte Antigen I (HLA-I) to facilitate antigen presentation.
[1,2] It has long been appreciated that glomerular filtration is the major pathway for the elimi-
nation of β2M. [3–7] Residual renal function (RRF), inflammation and malnutrition appear to
affect β2M concentration in patients with chronic kidney disease (CKD) [8–11] and end-stage
renal disease (ESRD) [12–17]
The main recognized manifestation of β2M accumulation in patients receiving long-term
dialysis is dialysis-related amyloidosis [18–22], but more recently β2M has also been linked to
higher mortality in hemodialysis (HD) patients [14,23,24], to aortic calcification and cardio-
vascular mortality in patients with non-dialysis dependent CKD [25]. Nevertheless, more effi-
cient dialytic removal of β2M has not equivocally translated into improved outcomes in
randomized controlled trials (RCT) of High Fluxmembranes [14,26] and on-line hemodiafil-
tration (HDF) [27–29] creating uncertainty regarding the clinical effectiveness of enhanced
middle molecule removal. Understanding of these discrepant findings and their implication for
the middle molecule toxin theory that has been the driving biological hypothesis for the major-
ity of randomized trials to date, requires one to simultaneously consider the ability of the avail-
able dialysis modalities to remove β2M and the considerable intra-individual, biological,
variability in the kinetics of β2M. However, a quantitative description of the relative importance
of intra-individual factors determining β2M concentrations among patients with impaired kid-
ney function is currently lacking.
This report aims to develop a population kinetic model incorporating the intra-individual
variability in generation, distribution and extrarenal elimination of β2M, which is then used to
describe the disposition of β2M under different HD regimes and levels of RRF. To develop this
population kinetic model, we first undertook a patient-level review and synthesis of the litera-
ture of clinical studies (either observational or interventional) regarding these kinetic parame-
ters of β2M in humans. We used these parameters to simulate β2M concentrations and relative
survival in a population of ESRD patients with different levels of RRF, using previously reported
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dose response relationships between predialysis β2M concentration and survival [30]. In these
simulations we contrasted the intervention protocols utilized in RCTs of HD patients vis-à-vis
RRF as determinants of patient survival.
These large scale simulations allowed us to conduct in-silico randomized controlled trials of
different dialysis modalities i.e. low flux (LF, negligible β2M clearance) and high flux (HF,
higher β2M clearance) membranes in conventional thrice-weekly HD, HF dialysis in short and
long daily sessions and HDF. Our simulations not only recapitulate the design and findings of
previously reported trials in dialysis, but also generate hypotheses about novel targets of inter-
vention in nephrology and trial designs for the validation of the middle molecule hypothesis.
Materials and Methods
Systematic review of studies of β2M kinetics
These were identified by searching MEDLINE with the following (text) string: “(beta 2 micro-
globulin) AND (kinetic OR kinetics OR model OR models) AND (mathematical OR compart-
mental OR compartment OR simulation) AND (volume OR generation OR clearance OR
dialysis OR renal OR dialytic OR production)” supplemented by manual inspection of the bib-
liography of indentified papers in a previous narrative review. [31] We did not screen articles
but proceeded to full text of all studies indentified through the Medline search, to exclude those
that were review articles, in-vitro or animal investigations, simulation experiments, failure to
employ a kinetic model, or reported aggregate rather than subject level data (exclusion criteria).
We included papers if they had used a compartmental model to study β2M kinetics, reported
patient-level data and were published in English prior to 2015. As this was not an outcomes
systematic review, we did not register our systematic review prospectively. Two investigators
(MR, and CA) jointly extracted the data (values of kinetic parameters about the generation,
intra-compartmental distribution, volume of compartments, non-renal clearance of β2M) from
each individual participant in each study using a piloted form. This form and the patient level
data extracted from our evidence synthesis are given in S1 Table.
Since classical techniques for the assessment of bias e.g. funnel plots are not applicable when
the studies synthesized lacks a discrete health outcome, we were not able to conduct a formal
analysis of bias with these methods. However for each study we evaluated the number of
parameters reported, those fixed and those unreported by the investigators as an indicator for
bias. We considered studies that did not report (or fixed to a specific value) of at most one
parameter as studies with minimal risk of bias. As the number of parameters with fixed (or
unreported values) increases, the estimated values of the remaining parameters becomes more
and more dependent on the specific assumptions of the investigators and thus the risk for bias
increases. Further details are provided in the Prisma Checklist (S2 Text).
Compartmental simulation modeling
B2M kinetic simulations were based on the variable volume model [32–34] with two compart-
ments (S1 Text and S1 Fig) incorporating inter and intra-dialytic generation, residual renal
clearance, non-renal (extrarenal) clearance and dialytic routes of elimination. We simulated
the kinetic parameters of 10,000 patients from the scaled–for–weight distributions of the popu-
lation mean and standard deviation estimated from the literature synthesis at different levels of
RRF (0–10 ml/min) and under regimes of conventional, thrice-weekly HD with either LF or
HF dialyzers, short and long-daily HF HD and on-line HDF. Dialysis-related parameters
reflected the patterns observed in FHN [35,36], HEMO [37] and HDF trials (Dutch CON-
TRAST [27], Spanish ESHOL [28], Turkish OL-HDF [29]), with specific details in Supplemen-
tary Methods in S1 Text. The purpose of these large scale simulations of patients with their
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unique set of generation/distribution/extrarenal clearance parameters and dialysis settings
(dialyzer specifications, treatment time, blood flow rate, ultrafiltration and infusion rate of
replacement fluid) was to summarize the effects of different interventions on β2M exposure.
Statistical Analysis
Estimation of population kinetic parameters. We analyzed studies that collected multi-
ple measurements in the same individual with a bi-level mixed-effect model accounting for
individual (first level) and study (second level) heterogeneity; all other studies were analyzed
with a random-effects model with a single (study) random effects model. Parameters were log-
transformed prior to mixed-effect modeling of the population mean and (log-) variance, which
was estimated by the between individual (two level models) or within study (one level model)
standard error. Results are reported as means (SE) for the mean and the logarithm of the stan-
dard deviation of each log-transformed kinetic parameter. Furthermore, we calculated the pop-
ulation distribution of the untransformed parameters by transforming out of the logarithm
and using the properties of the lognormal distribution. The volume of the two distribution
compartments of β2M were analyzed both as absolute as scaled (to body weight) numbers. No
other analyses e.g. meta-regression were performed on these data.
Analyses of simulation modeling results. We assessed treatment related exposures to
β2M under time-dependent and peak-dependent toxicity perspectives by computing weekly
Time Averaged Concentrations (TAC) and mid-weekly pre-dialysis plasma (Cp) concentra-
tions respectively. The relationship between TAC and Cp was analyzed via linear regression for
all combinations of dialysis interventions and RRF levels. Dialytic interventions were compared
on the basis of both TAC and Cp with a paired t-test. We assumed the following relationship
between the relative risk (RR) of death and quintiles of cumulative predialysis β2M concentra-
tion observed over seven years in HEMO [30]: 1.0 (β2M< 27.5mg/l, referent), 1.11 (β2M:27.5-
35mg/l), 1.35 (β2M:35–42.5mg/l), and 1.50 (β2M>42.5mg/l), obtained by averaging the risk in
the last two quintiles due to the plateauing of the risk-exposure curve reported by the original
investigators). Intra-individual changes in cumulative predialysis β2M concentration (averaged
over the last two weeks of each simulation) between any two regimes in our simulations were
thus converted to differences in RR. The latter, averaged over all individuals yield counterfac-
tually the Average Causal Effect (ACE). [38] We employed the connection between the ACE, a
statistical measure of cause and effect, and the treatment effect estimated by RCTs [39] to inter-
pret findings of recent trials and suggest hypotheses for testing in future studies. All analyses
were performed in R (v2.15.1–3.1.3).
Results
Studies
A PUBMED search identified 57 papers (S2 Table). An additional eight papers were identified
by manual searches of the bibliography of the identified papers and a previous narrative review
[31]. Four papers out of the fifty identified through database searching fulfilled the criteria for
inclusion and met no criteria for exclusion after full text review (see S2 Table for the references
of these fifty papers and the inclusion/exclusion status). Three of the eight papers identified
through other sources were excluded due to the use of highly compartmentalized, models that
could not be reduced to the model utilized in this report [40,41],[42] yielding a total of nine
separate studies (Fig 1). Four of the studies were at minimal risk of bias (one or none fixed/
unreported parameters). Studies included in the systematic review, used experimental methods
ranging from isotopic dilution to profiling of intra/inter dialytic concentration changes
(Table 1) to determine β2M kinetics. In total, these studies reported 156 evaluations of one or
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more parameters of the compartmental model of β2M in 106 patients (Table 1). Most of the
patients (74/106) were on dialysis with minimal RRF, facilitating thus the estimation of the
non-renal (“extrarenal” [33]) clearance (KER) of β2M. In subjects with normal kidney function,
separate estimation of renal clearance (KR) and KER clearances is not possible, so that only a
total body clearance (equal to KR+KER) can be estimated.
Population β2M Estimates
Parameter estimates, and the resultant population distribution values (median, upper and
lower 2.5% tail) are summarized in Table 2. In normal subjects kidney function is the major
determinant of total body clearance as the estimated median KR+KER, was equal to 90.43 ml/
min vs. 2.92 ml/min for KER in patients on dialysis.
Hemodialysis Simulations
Residual renal clearance is a major determinant of β2M concentration in dialysis
patients. The simulated predialysis β2M concentrations of different dialysis regimens at vari-
ous levels of KR are shown in Fig 2. The highest concentrations were seen in patients on LF HD
irrespective of RRF due to minimal dialytic clearance. Conventional HD, short-daily or long-
daily HF and HDF resulted in decreased β2M relative to LF HD. Time averaged concentrations
(TAC) and predialysis concentrations were highly and positively correlated across all combina-
tions of RRF and dialytic interventions (r2>0.99).
Regression analysis (Fig 3) also demonstrated a high numerical agreement between the two
measures, with the slopes in linear regression being close to unity especially for higher levels of
RRF. Nevertheless, this agreement differed for the different modalities; although the TAC was
Fig 1. PRISM flow chart of the systematic review of human studies examining the compartmental
kinetics of beta 2 microglobulin. A total of 58 studies were identified through a database (Medline) and
other sources (examination of references of qualifying articles from the literature review, previous narrative
review. A total of nine studies met all inclusion and none of the exclusion criteria.
doi:10.1371/journal.pone.0153157.g001
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within 8% of the predialysis level for most modality, RRF combinations, it diverged more than
10% in long-daily or HDF at lower RRF levels.
Table 3 shows the pair-wise mean differences in β2M concentrations between different regi-
mens at different levels of RRF. It is only in the absence of RRF (KR = 0 ml/min) that higher
dialytic removal of β2M in the form of short-daily (SD vs. HF, Table 3), or HDF (HDF vs HF,
Table 1. Published patient level data regarding β2 microglobulin kinetics.
Study Number: Measurements
/patients
Groups (N) Kinetic
Model
Parameters
Estimated &
Reported
Fixed Unreported
Karlson et al
1980[43]°
12 / 12 Control (6) MM (2) RA (1) CGN (2)
RI (1)
2C G, KIC, KR+KER, VP,
BW
None VNP
Vincent et al
1980 [44]*
12 / 12 Control (2) HD (2) CKD (4)
Transplant (4)
2C G, KIC, KR+KER, VP,
BW
None VNP
Maeda et al 1990
[45] ╪
11 / 11 HDF (11) 1C G, BW VT None
Floege et al 1991
[46] ¶
16 / 16 Normal (5) LF-HD (6) HF-HD (5) 2C G, KIC, KER, BW VP VNP
Odell et al 1991
[47] ┼
8 / 5 LF-HD (4) HF-HD (4) 3C G, KIC, KER, VP,
VNP, BW
None None
Vincent et al
1992[48] §
22 / 22 Normal (5) LF-HD (5) HF-HD (5)
HDF (4) CAPD (3)
3C G,KIC, KER,VP, VNP,
BW
None KIC, VNP
Xu et al 2001[49]
+
50 /10 LF-HD (10) HF-HD (40) 2C G, KER, BW VP,VNP, VT,
KIC
None
Stiller et al 2002
[32] ×
15 / 8 HF-HD (15) 2C G, KIC, VP,VP: VNP,
BW
KER VP
,VNP
Ward et al 2006
[33] ¤
10 / 10 HF-HD (10) 2C G, KIC, VT VP: VNP,
KER
BW
Abbreviations: MM (Multiple Myeloma), RA (Rheumatoid Arthritis), CGN (Chronic Glomerulonephritis), RI (Renal Insufﬁciency), LF-HD (Low Flux
Hemodialysis), HF-HD (High Flux Hemodialysis), HD (Hemodialysis), HDF (Hemodiaﬁltration), Continuous Ambulatory Peritoneal Dialysis (CAPD) 1-3C:
Model with 1, 2 or 3 Compartments. Kinetic Parameters: β2 Microglobulin Generation Rate (G), Intercompartmental Exchange Rate Constant (KIC),
Extrarenal Clearance (KER), Renal Clearance (KR), Perfusing/Plasma/Primary Distribution Volume (VP), Non-Perfusing/Tissue/Extravascular Distribution
Volume (VNP), Total Distribution Volume (VT = VP + VNP), Body Weight (BW).
Notes
°All subjects had simultaneous creatinine measurements that were  1.2 mg/dl. VNP was calculated from the forward and reverse intercompartmental
transfer constants reported in the paper, assuming a sieving coefﬁcient equal to one.
* Patients had simultaneous β2 microglobulin and inulin clearance determinations. Only one of the four transplant patients had a normal inulin clearance,
but this was determined just before an acute rejection episode. The ﬂux of the patients on dialysis was not speciﬁed in the manuscript. VNP was calculated
from the forward and reverse intercompartmental transfer constants reported in the paper, assuming a sieving coefﬁcient equal to one.
╪ Volume of distribution ﬁxed to a multiple of the plasma volume using anthropometric and previous kinetic data [44].
¶ Fixed to anthropometric estimate for blood volume for normal individuals adjusted for hematocrit.
┼ Patients were receiving low ﬂux dialysis in the ﬁrst study, but high ﬂux dialysis on the second study. Three patients were assessed on both high and low
ﬂux dialyzers. VNP was calculated by summing the reported volumes of the two non plasma compartments. The overall intercompartmental rate transfer
constant was set equal to the average of the fastest and the sum of the rate constants to the two non-vascular compartments.
§ Calculated from the reported value of Vp and the relative size of plasma and tissue pools.
+ only a single value for the extrarenal clearance was reported; generation rate was assumed not to be inﬂuenced by the change in ﬂux; VT was set equal
to 40% of the anthropometrically estimated plasma water and the ratio VP / VNP was assumed to be equal to 1:4; KIC was set equal to 50 ml/min for all
patients.
× KER set to 3.13 ml/min for all patients. VP and VNP calculated from the reported total distribution volume and the ratio of the two compartments.
¤ The authors assumed a constant ratio VP / VNP equal to 1:3 and KER of 3 ml/min for all patients.
Patient’s weight was not reported in the manuscript.
doi:10.1371/journal.pone.0153157.t001
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Table 3) had a substantial effect on β2M relative to conventional HF HD. Similarly, long daily
dialysis consistently resulted in lower concentrations of β2M concentrations; the difference
between the two modalities widened as renal function declined (LD vs. SD, Table 3). Finally,
HDF resulted in predialysis β2M concentration that was very similar to the one achieved with
short-daily dialysis at all levels of RRF (HDF vs SD Table 3).
Comparisons based on TAC yielded congruent findings with respect to the relative effi-
ciency of the different dialysis regimes and the role of RRF (Table 4). In these comparisons, the
absolute difference in TAC (Table 4) between short-daily dialysis and HDF was much larger
than the corresponding difference in Cp (shown in Table 3), suggesting that short-daily yields
somewhat lower exposures than HDF compared to the expectations based on predialysis
concentrations.
Residual renal function is more important than enhanced dialytic removal in determin-
ing β2M related outcomes in hemodialysis. Reduction in residual KR from 10 ml/min to nil
resulted in an increase in the percentage of patients whose β2M concentration category (<27.5
mg/l, 27.5–35 mg/l, 35–42.5 mg/l and>42.5 mg/l) increased e.g. 20%-80% in patients receiving
HDF and LF respectively. This was associated with an increase in the predicted RR (Fig 4), that
was modified by the dialysis regime: 1.32 (LF), 1.21 (HF), 1.13 (SD), 1.03 (LD), and 1.13
(HDF). The magnitude of the RRs far exceeded the reductions in mortality that were predicted
on the basis of enhanced dialytic removal of β2M (Fig 5), e.g. less than 8% for comparisons of
HF vs. LF, short-daily or long-daily, and HDF vs. LF, HF or short-daily when KR was 2 ml/min.
Table 2. β2 microglobulin population kinetic parameters and quantile values.
Mixed Model Parameter
Estimates¶
Population
Distribution Values╪
Kinetic Parameter Number (studies) Number:
measurements/
patients
Mean
(SE)
Logarithm of the
Standard Deviation (SE)
Median Q025 Q975
Generation Rate (mg/kg/day) 8[32,43–49] 146 / 96 1.1
(0.08)
-1.1 (0.1) 3.01 1.57 5.78
Intracompartmental Rate Transfer
(ml/min)
6
[32,33,43,44,46,47]
73 / 63 4.23
(0.21)
-1.26 (0.25) 68.54 39.37 119.3
Extrarenal Clearance (ml/min) 6[44–49] 59 / 56 1.07
(0.13)
-0.95 (0.12) 2.92 1.37 6.25
Total Body Clearance in Controls
(ml/min)*
3[43,46,48] 19 / 19 4.5
(0.17)
-1.65 (0.18) 90.43 62.1 131.7
Total Volume of Distribution (L) 6
[32,33,43,44,47,48]
79 / 69 2.4
(0.06)
-1.31 (0.08) 11.14 6.57 18.90
Total Volume of Distribution (% BW) 5[32,43,44,47,48] 69 / 59 -1.73
(0.09)
-1.44 (0.11) 17.73 11.13 28.24
Perfusing Compartment Volume (%
BW)
5[32,43,44,47,48] 69 / 59 -3.06
(0.15)
-1.89 (0.18) 4.67 3.47 6.28
Ratio Of Non-Perfusing to Perfusing
Compartment Volume
5[32,43,44,47,48] 69 / 59 1 (0.15) -1.53 (0.29) 2.72 1.78 4.15
Notes
¶ Parameters obtained by a linear mixed model for the logarithm of each kinetic parameter. The model assumes that each kinetic parameter follows a log
normal distribution (or equivalently that their logarithms are normally distributed). For each kinetic parameter the location and the logarithm of the variance
of the corresponding log-normal distribution was estimated via a mixed effects model.
* Excluding the two controls from the study by Vincent, Pozet and Revillard [44] since the values for these 2 individuals were 5–6 times smaller than the
simultaneously determined (via inulin clearance) GFR values.
╪ Q025: lower 2.5% quantile, Q975: upper 2.5% quantile.
doi:10.1371/journal.pone.0153157.t002
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In the absence of kidney function, the smallest RRs were seen in HDF and long-daily vs. LF and
HF, and were in the order of 0.85. Under the remaining scenarios, dialysis with a regime that more
efficiently removes β2M is predicted to be associated with single digit improvement in the RR.
The estimated dialytic effects on β2M category and predicted survival were not uniform
across subgroups defined on the basis of quartiles of increasing β2M generation rate. Relative
to LF dialysis, adoption of HF membranes would be expected to reduce mortality by more than
10% in patients of the lower two (Q1-2) quartiles (Fig 6), but the effect is smaller and reaches a
plateau for higher generation rates. A similar pattern was noted for HDF or short-daily vs. HF
dialysis for the Q4 subgroup. Long-daily regimes are anticipated to improve outcomes more
for patients at Q2-Q4 (15–19%) rather than those who generate β2M at the lowest generation
rate (~7%). As anticipated dialysis effects were quantitatively more important for patients with
higher generation at higher levels of RRF (i.e., the RR of 0.95 for short-daily vs. HF was
observed for Q1 patients at a KR of 0 ml/min vs. 10 ml/min for Q4 patients).
Fig 2. Simulated β2M concentrations at different levels of residual renal clearance and dialysis regimes. LF: Low Flux Dialysis, HF: High Flux Dialysis,
SD: Short Daily Dialysis with High Flux dialyzers (6 times a week, ~ 2½ hrs per session), LD: Long Daily Dialysis with High Flux dialyzers (6 times a week, 6 ⅓
hrs per session), HDF = postdilution online hemodiafiltration.
doi:10.1371/journal.pone.0153157.g002
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Fig 3. Relation betweenmid-week simulated predialysis and weekly time averaged β2M concentrations at different levels of residual renal
clearance and dialysis regimes.Correlation coefficients (r2) and regression equations relating the two measures of exposure (gray line) are shown. LF:
Low Flux Dialysis, HF: High Flux Dialysis, SD: Short Daily Dialysis with High Flux dialyzers (6 times a week, ~ 2½ hrs per session), LD: Long Daily Dialysis
with High Flux dialyzers (6 times a week, 6 ⅓ hrs per session), HDF = post dilution online hemodiafiltration. Cp: predialysis plasma concentration, TAC: Time
Averaged Concentration.
doi:10.1371/journal.pone.0153157.g003
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Discussion
This report demonstrates estimated predialysis β2M concentrations averaging over the popula-
tion variability in generation, distribution and extrarenal clearance of β2M under different lev-
els of RRF. Since RRF is a major determinant of β2M in dialysis patients, increased dialytic
removal becomes clinically important only when RRF has declined to below 2ml/min. Dialysis
effects on survival outcomes related to β2M levels were moderate and heterogeneous in sub-
groups of patients of different generation rates at all levels of RRF and for a wide spectrum of
dialysis regimens.
The population kinetic model reproduces experimental patterns observed in early studies of
dialysis patients [13,30,31,50–52]. More specifically, we anticipated a large influence of RRF on
plasma β2M concentration, particularly when the former declines below 2 ml/min. In retro-
spect, this prediction is not surprising but we derive this relation from first principles and in a
quantitative fashion. This allows our numerical evaluations to generate testable hypotheses
that can be verified or refuted by empirical data. In HEMO, predialysis β2M concentrations
were higher in anuric patients [30] and declined curvilinearly for higher residual urea clear-
ances (e.g. see Fig 3[30]), a pattern similar to the one described in this report. In the CON-
TRAST trial of HDF, the average β2M concentration in patients dialyzing with LF membranes
Table 3. Mean pair wise difference in predialysis β2 microglobulin concentration (in mg/L) and associated 95% confidence interval as a function of
residual renal clearance.
HF vs LF SD vs HF LD vs SD HDF vs HF HDF vs SD
KR (ml/min) Estimate 95%CI Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
0 -16.75 -16.45, -17.04 -7.51 -7.62, -7.41 -9.69 -9.80, -9.57 -7.47 -7.59, -4.47 0.04 -0.03, 0.12*
2 -5.00 -5.11, -4.90 -3.95 -4.00, -3.90 -5.42 -5.48, -5.36 -3.21 -3.26, -3.15 0.74 0.70, 0.79
4 -2.38 -2.42, -2.34 -2.45 -2.48, -2.42 -3.40 -3.44, -3.36 -1.64 -1.66, -1.61 0.81 0.78, 0.84
6 -1.25 -1.23, -1.27 -1.66 -1.68, -1.64 -2.28 -2.31, -2.26 -0.91 -0.93, -0.89 0.75 0.74, 0.77
8 -0.67 -0.69, -0.66 -1.20 -1.22, -1.19 -1.61 -1.63, -1.59 -0.55 -0.56, -0.54 0.65 0.64, 0.67
10 -0.40 -0.41, -0.40 -0.90 -0.92, -0.89 -1.18 -1.19, -1.16 -0.35 -0.36, -0.34 0.55 0.54, 0.57
Notes: Differences and 95% conﬁdence intervals (95% CI) were computed by paired t-test; unless stated otherwise, p for all comparisons is <0.001
*p = 0.26
HF = High Flux thrice weekly dialysis, LF = Low Flux thrice weekly dialysis, SD = Short Daily dialysis, LD = Long Daily dialysis, HDF = post-dilution online
hemodiaﬁltration
doi:10.1371/journal.pone.0153157.t003
Table 4. Mean pair wise difference in the Time Averaged Concentration (TAC) of β2 microglobulin (in mg/L) and associated 95% confidence inter-
val as a function of residual renal clearance.
HF vs LF SD vs HF LD vs SD HDF vs HF HDF vs SD
KR(ml/min) Estimate 95%CI Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
0 -23.58 -23.95, -23.21 -6.20 -6.23, -6.11 -10.74 -10.86, -10.62 -10.19 -10.32, -10.06 -3.99 -4.07, -3.91
2 -8.96 -9.07, -8.86 -3.19 -3.23, -3.15 -6.49 -6.56, -6.42 -5.31 -5.37, -5.25 -2.12 -2.16, -2.08
4 -4.82 -4.89, -4.78 -1.96 -1.99, -1.94 -4.38 -4.43, -4.34 -3.28 -3.31, -3.24 -1.31 -1.33, -1.28
6 -3.03 -3.07, -3.00 -1.33 -1.35, -1.32 -3.17 -3.20, -3.14 -2.22 -2.25, -2.20 -0.89 -0.91, -0.87
8 -2.89 -2.11, 2.07 -0.97 -0.98, -0.96 -2.41 -2.43, -2.39 -1.61 -1.63, -1.60 -0.64 -0.66, -0.63
10 -1.53 -1.54, -1.51 -0.74 -0.75, -0.73 -1.89 -1.91, -1.87 -1.22 -1.24, -1.21 -0.49 -0.50, -0.48
Notes: Differences and 95% conﬁdence intervals (95% CI) were computed by paired t-test; p for all comparisons is <0.001. HF = High Flux thrice weekly
dialysis, LF = Low Flux thrice weekly dialysis, SD = Short Daily dialysis, LD = Long Daily dialysis, HDF = post-dilution online hemodiaﬁltration.
doi:10.1371/journal.pone.0153157.t004
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and an eGFR of 2.0 ml/min/1.73 m2 at baseline was 30.7–32.3 mg/L, which is in close agree-
ment with our estimate of 29.9 mg/L. [27] At a higher, semi-quantitative level, our analyses
suggest that interventions that increase dialytic removal of β2M (i.e., use of HF membranes,
addition of convective clearance in the form of HDF, increase in both frequency and duration
of treatments) will be masked until RRF is substantially reduced in accordance with reports in
HF dialysis [51] and on-line HDF [13,16].
Our findings provide a framework to reconcile reports suggesting that higher dialytic
removal (HDF vs. HF) does not have a substantial impact on predialysis β2M concentration
[28,29,53]. These discrepancies can be understood by highlighting the importance of both RRF
and the (unmeasured) generation rate as determinants of the β2M response to dialysis. These
HDF studies enrolled prevalent patients (median time on dialysis: 28–68 months) and with the
Fig 4. Simulated changes in β2M and predicted Relative Risk (RR) of death at different levels of renal function. For each dialysis regime we
calculated: i) the percentage of patients undergoing a change in their cumulative predialysis β2M concentration (categorically classified as <27.5 mg/l, 27.5–
35 mg/l, 35–42.5 mg/l and >42.5 mg/l) for the different levels of residual renal function (KR) relative to the baseline measurement when KR = 10 ml/min ii) the
associated prediction for the RR. Within each dialysis modality, the referent is the state with KR = 10 ml/min
doi:10.1371/journal.pone.0153157.g004
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exception of the study by Ward, [53] provided minimal data on RRF. Hence, in studies infer-
ring the response of β2M to more efficient dialysis one should adjust for these parameters either
directly by measuring RRF, or indirectly by using additional patient level covariates that poten-
tially correlate with the generation rate of middle molecules.
Another novel feature of this report is the adoption of a counterfactual perspective in the
population-level evaluation of different dialysis regimes. This perspective allowed us to predict
relative changes in survival associated with changes in β2M (the prototypical middle molecule
[54]) exposure. In ESRD more robust evidence that higher β2M concentrations are associated
with worse survival comes from the HEMO study cohort, [23,30] in which β2M levels were
assessed prospectively and repeatedly over time. The apparent dose response relationship in
HEMO was observed in a cohort of patients with negligible RRF (only 14% of the 1704 patients
had RRF>0.75 ml/min at study enrollment), and was detected with time-updated survival
models in the presence of extensive multivariable adjustment including RRF. On the other
Fig 5. Simulated changes in β2M and predicted Relative Risk (RR) of death associated with enhanced dialytic removal. At each level of residual renal
function (KR) we calculated: i) the percentage of patients with a change in the cumulative β2M concentration (categorically classified as <27.5 mg/l, 27.5–35
mg/l, 35–42.5 mg/l and >42.5 mg/l) between techniques of higher and lower dialytic removal of β2M ii) the associated prediction for the RR.
doi:10.1371/journal.pone.0153157.g005
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hand, cross-sectional, observational studies utilizing single measurements of β2M yielded par-
tially conflicting associations [24],[55]. More recently, associations have been reported between
β2M and survival (all-cause and cardiovascular in NHANES [56] and ARIC [57]), cardiovascu-
lar events and calcification in CKD [25], early-onset atherosclerosis in ESRD [58], stroke [59],
peripheral arterial disease [60–63], and mortality in patients undergoing coronary angiogra-
phy. [64] Although observational, these associations have held against adjustments for known
risk factors and the prevailing level of kidney function (as assessed with cystatin-C or eGFR)
suggesting that β2M elevations may have pathologic significance above and beyond its associa-
tion with glomerular filtration.
These clinical and basic science observations suggest that it is at least possible that β2M may
be directly, rather than indirectly, e.g. as a surrogate of RRF, implicated in the heightened mor-
bidity and mortality in ESRD. Thus, combination of the population kinetic model with
Fig 6. Simulated changes in β2M and predicted Relative Risk (RR) of death associated with enhanced dialytic removal at different quartiles (Q1-4)
of generation rate. At each level of residual renal function (KR) and quartile of reuse we calculated: i) the percentage of patients with a change in the
cumulative β2M concentration (categorically classified as <27.5 mg/l, 27.5–35 mg/l, 35–42.5 mg/l and >42.5 mg/l) between techniques of higher and lower
dialytic removal of β2M ii) the associated prediction for the RR.
doi:10.1371/journal.pone.0153157.g006
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concentration-effect relationships, known as an exposure-clinical response model in clinical
pharmacology [65], can be considered a research tool that facilitates quantitative predictions
and testable hypotheses to be generated. One such prediction is that total loss of RRF will be
associated with worsened survival in HD. For US patients, who initiate Conventional thrice-
weekly HD at an average kidney function of 10 ml/min [66] the RR associated with total loss of
kidney function is over 20% (>30% for LF dialysis) in our simulations. This is approximately
60% of the corresponding estimate reported in a prospective Dutch cohort [67]. It is tempting
to hypothesize that loss of middle molecule clearance is a large component of the heightened
mortality risk due to the loss of RRF observed in the real world, while the remaining excess
mortality is explained by the imperfect capability of renal replacement therapies to restore
fluid, electrolyte and other uremic toxin (e.g. bound solutes) [68–70] homeostasis.
Our simulations predict that higher dialytic removal of β2M will not affect the RR for death
until RRF has declined below 2ml/min. This was seen for all comparisons based on interven-
tions that have been tested in actual medium-large scale RCTs: HF vs. LF (HEMO [14] and
MPO [26]), SD vs. HF [35], LD vs. HF [36], LF vs. HDF (CONTRAST [27]), HF vs. HDF
(ESHOL [28] and Turkish trials [29]) as well as trial configurations that to our knowledge have
not been reported in the literature: SD or LD vs. HDF. Furthermore, the benefits at the popula-
tion level that are likely to accrue due to higher middle molecule removal from such interven-
tions are unlikely to be large relative to the de-facto standard of HF dialysis [71] unless
treatment time, frequency and possibly convective clearance [72] are all increased. Overall
these predictions are consistent with the findings of RCTs in this area, yet suggest that sub-
groups defined by toxin generation rate may receive benefit more than others. To our knowl-
edge, this hypothesis has never been evaluated in either a RCT or an associational study
context. Hence, the availability of a population kinetic model described herein provides an
opportunity to directly test this hypothesis by yielding a tool that can be used to characterize
kinetics in an individualized manner and use this information in a research setting. This is sim-
ilar to the use of quantitative models in pharmacology [73] to estimate patient specific variables
that are used to individualize plasma drug concentrations or pharmacodynamic responses in
research or clinical care settings. In this light, the observation that the predialysis β2M concen-
tration is numerically very close to the TAC of β2M (at least for dialysis practices that are
widely employed in the US), suggests that predialysis β2M concentration monitoring may offer
some of the benefits of more extensive modeling.
From a practical standpoint, the numerical simulations reported herein support the argu-
ment that delaying loss of kidney function should be counted among the therapeutic HD goals.
This argument agrees with a large body of emerging clinical data [74] associating RRF with
improved survival, lower hospitalizations, improved anemia and phosphorus management,
better volume management and decreased left ventricular hypertrophy. Thus, aiming only for
“more dialysis” without considering RRF is too narrow of a focus if better outcomes are to be
attained. The recent report that frequent, prolonged HD is associated with faster declines in
RRF [75] while short frequent sessions [75] or HDF [76] may have a neutral or even positive
impact in sustaining kidney function, suggests that a tailored approach to dialysis prescription
that considers both dialytic and kidney function is required.
The findings and interpretations in this report should be viewed in light of certain limita-
tions in the source data, and in the kinetic and outcome models used. Firstly, the available
kinetic studies of β2M involved only a small number of patients and it is possible, that previous
research failed to include a representative sample from the human population. Furthermore,
our search strategy may have failed to identify all relevant publications. Nevertheless, our simu-
lations reproduced a number of experimental findings so that a strong bias from these two
sources is unlikely. Secondly, we have assumed that higher dialytic clearance will affect β2M
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concentrations only through the dialytic removal of the molecule, without affecting its genera-
tion rate. Although suggested by some in vitro studies [77,78], other ex vivo [79,80] and in vivo
[81] investigations did not demonstrate an effect of dialyzer flux on β2M gene transcription or
protein expression, thus providing empiric support for our assumptions regarding this matter.
Thirdly, a few studies have raised the possibility that a third compartment [47,82] may be
needed to accurately describe β2M kinetic behavior in patients undergoing long-term HD (>6
years). Therefore, in this report we limited our simulations to 3 months, an interval much lon-
ger than the 2–3 weeks needed to evaluate the effects of a given dialysis procedure [47], but
shorter than the time over which the two-pool model would potentially lose its accuracy.
Finally, the association between middle molecules and outcomes was assessed using a single
biomarker (β2M).
One possibility is that β2M, although extensively studied, is an imperfect marker for the
removal of the entire spectrum of the peptides/proteins of molecular weight>500 kDa classi-
fied as middle molecules. [53,72] Notwithstanding the observations that other middle mole-
cules (beta trace protein [83] or cystatin-C [84]) have also been linked to HD outcomes this is a
major limitation due to gaps in the existing literature that only further experimental research
can resolve. For example, other uremic solute categories (such as the protein bound toxins)
may even be more important than middle molecules and these are more efficiently cleared by
larger dialyzers in prolonged sessions [68] or by HDF [69,85]. Supporting recent appraisals
and criticisms [86–88], these considerations suggest the need for a more rigorous evaluation of
longitudinal changes in a number of candidate uremic toxins in relation to patient outcomes
beyond β2M. Such a task may be facilitated by targeted analyses in existing biorepositories
[89,90] established in the context of RCTs or through establishment of collaborative efforts
[91] in prospectively followed observational cohorts. [83]
In summary, we have undertaken a quantitative analysis of the available kinetic studies of
β2M in order to simulate β2M concentrations and associated changes in survival across a wide
range of dialysis regimes ranging from conventional thrice weekly HD to long daily sessions
with HF dialyzers and HDF. These simulations support many clinical observations over the
last 30 years while suggesting that optimal middle molecule dialysis may critically depend on
the preservation of RRF. Future studies should examine the validity of these predictions against
non-standard schedules of frequent short and long HD and HDF and test the utility of the esti-
mated population model in individualizing treatment parameters.
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